Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
KANDLELIT-004
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- NCT06345729 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Calderasib; Placebo; Pembrolizumab
- Arms
- Calderasib with Pembrolizumab · Experimental
- Placebo with Pembrolizumab · Active comparator
- Enrollment
- 348 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- May 24, 2024
- Primary completion
- Jan 24, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06345729 · updated Oct 26, 2026